**Specifications table**TableSubject areaMedicineMore specific subject areaAnalysis of data on omega-3 fatty acids in critical care nutritionType of dataTables and figuresHow data was acquiredData were acquired through meta-analysis of 24 RCT׳s on enteral omega-3 fatty acid supplementation in critically ill patientsData formatAnalyzedExperimental factorsCritically ill patients receiving enteral omega-3 fatty acid supplementation included in randomized controlled trials were includedExperimental featuresForest plots were generated and relative risk ratio׳s calculated to show the effects of omega-3 fatty acid supplementationData source locationA systematic review was conducted to identify all relevant randomized clinical trials published before January 2018 in MEDLINE, Embase, CINAHL and the Cochrane Central Register of Controlled Trials.Data accessibilityA systematic review was conducted to identify all relevant randomized clinical trials published before January 2018 in MEDLINE, Embase, CINAHL and the Cochrane Central Register of Controlled Trials.

**Value of the data**•The data on tolerability and adverse events are helpful in a risk-benefit analysis of omega-3 supplementation in the critically ill.•Data on ICU and hospital mortality provide more information on safety of omega-3 interventions.•Data on age distribution between studies may be helpful in interpretation of results and may give rise to specific treatment of age-groups.•Data on EPA and DHA baseline and follow-up levels may be of value in interpretation of the effects of omega-3 supplementation as they may be related to serum levels.

1. Data {#s0005}
=======

We share data regarding ICU and hospital mortality, age distribution between included studies in [@bib1], tolerability and adverse events of enteral omega-3 supplementation compared with placebo in the critically ill. [Fig. 1](#f0005){ref-type="fig"} shows the effects of fish oil supplementation on ICU mortality in different ICU populations. [Fig. 2](#f0010){ref-type="fig"} shows the effects of fish oil supplementation on hospital mortality in different ICU populations. In [Fig. 3](#f0015){ref-type="fig"} the effects of fish oil supplementation on 28-day mortality, comparing old versus new randomized controlled trials (RCTs) are reported. In [Fig. 4](#f0020){ref-type="fig"} the effects of fish oil supplementation on 28-day mortality, comparing high versus low quality RCTs are shown.Fig. 1The effects of fish oil supplementation on ICU mortality in different ICU populations. ARDS: Acute respiratory distress syndrome; ICU: Intensive Care Unit; CI: confidence interval.Fig. 1Fig. 2The effects of fish oil supplementation on hospital mortality in different ICU populations. ARDS: Acute respiratory distress syndrome; ICU: Intensive Care Unit; CI: confidence interval.Fig. 2Fig. 3The effects of fish oil supplementation on 28-day mortality, comparing old versus new RCTs. CI: confidence interval.Fig. 3Fig. 4The effects of fish oil supplementation on 28-day mortality, comparing high versus low quality RCTs. CI: confidence interval.Fig. 4

Adverse events registered in the trials included in [@bib1] are reported in [Fig. 5](#f0025){ref-type="fig"}.Fig. 5Adverse events in RCTs comparing fish oil supplementation with control enteral feeding. CI: confidence interval.Fig. 5

[Table 1](#t0005){ref-type="table"} reports baseline and follow-up EPA and DHA levels. Furthermore, [Table 2](#t0010){ref-type="table"} reports on age distribution in the studies included in [@bib1]. Additionally, tolerability of omega-3 supplementation in ICU patients is reported in [Table 3](#t0015){ref-type="table"}.Table 1EPA and DHA levels before and after fish oil supplementation.Table 1StudyBaseline EPA levelsBaseline DHA levelsReached EPA levelsReached DHA levelsRemarksAtkinson 1998NRNRNRNRBower 1995NRNRIntervention group: 97% increase, *p* \< 0.01Intervention group: 72% increase, *p* \< 0.01Subset of 72 random patientsControl group: NS differenceControl group: NS differenceElamin 2012NRNRNRNRGadek 1999Intervention group: 0.4% of plasma phospholipid fatty acidsNRIntervention group day 4:6.9% of plasma phospholipid fatty acids, *p* \< 0.001NRExtracted from figuresControl group: 0.6% of plasma phospholipid fatty acidsIntervention group day 7:8.4% of plasma phospholipid fatty acids, *p* \< 0.001Control group day 4 and 7:0.1% of plasma phospholipid fatty acids, NSGalban 2000NRNRNRNRGrau-Carmo NR 2011NRNRNRNRHosny 2013NRNRNRNRJakob 2017NRNRNRNRKagan 2015Intervention group: 5.5 ± 1.5%Intervention group day 4: 6.0 ± 1.2%Omega-3 IndexControl group: 4.6 ± 0.9%Intervention group day 8: 6.8 ± 1.0%Analyzed only for patients completing 8 days of the study (*n* = 33 in the control group and *n* = 40 in study group)Control group day 4: 4.4 ± 0.8%Control group day 8: 4.5 ± 0.8 %Kieft 2005NRNRNRNRKudsk 1996NRNRNRNRMendez 1997NRNRNRNRMesejo 2015NRNRNRNRParish 2014NRNRNRNRPontes-Arruda 2006NRNRNRNRPontes-Arruda 2011NRNRNRNRRice 2011Intervention group: 2 mg/LNRIntervention group day 3, 6 and 12: approximately 16 mg/LNRExtracted from text and figure. Levels were measured in the first 60 patients. Because of unavailable samples, actual measurements are from 24 *n*−3 and 30 control patients at baseline (24 in each group at day 3, 17 in each group on day 6, and 8 *n*−3 and 9 control patients on day 12).Control group: 2 mg/LControl group day 3, 6 and 12: approximately 2 mg/LShirai 2015NRNRNRNRSinger 2006NRNRNRNRStapelton 2011NRNRIntervention group day 5: 31.9 mg/L (IQR 24.1--59.7)Intervention group day 5: 24.1 mg/L (IQR 15.8--39.8)Control group day 5:2.4 mg/L (IQR 1.5--6.3)Control group day 5: 12.8 mg/L (IQR 9.1--17.9)Thiella 2012NRNRNRNRTihista 2017NRNRNRNRWeimann 1998NRNRNRNRVan Zanten 2014Intervention group: (EPA+DHA):LCP ratio = 0.03 ± 0.01Intervention group day 4: (EPA+DHA):LCP ratio increase of 3.4%(95% CI, 3.0--3.8%)LCP = long-chain polyunsaturated fatty acidsControl group: (EPA+DHA):LCP ratio = 0.03 ± 0.01Intervention group day 8: (EPA+DHA):LCP ratio increase of 5.1%(95% CI, 4.6--5.5%)Control group day 4: (EPA+DHA):LCP ratio increase of −0.3%(95% CI, −0.4% to 0.2%)Control group day 8: (EPA+DHA):LCP ratio increase of −0.5% (95% CI, −0.6% to 0.4%)[^1]Table 2Age of study population of included RCTs.Table 2StudyAge interventionAge controlAtkinson 199863 (18--99)\*62 (18--87)\*Bower 199539 ± 18.239.9 ± 18.2Elamin 201250.0 ± 22.255.2 ± 16.5Gadek 199951 ± 251 ± 3Galban 200053.9 ± 18.557.7 ± 16.9Grau-Carmona 201162 (40--71)\^65 (51--76)\^Hosny 201352.8 ± 18.87 (intervention group A)50.5 ± 14.7753.1 ± 12.47 (intervention group B)Jakob 201765.3 (52.6--75.3)\^61.6 (48.6--71.3)\^Kagan 201542.9 ± 18.638.4 ± 16.8Kieft 200566.0 (49--74)\^68.0 (55--74)\^Kudsk 199634.3 ± 3.1^\#^31.8 ± 2.3^\#^Mendez 199728.2 ± 1.2^\#^35.3 ± 2.3^\#^Mesejo 201557 (43--70)\^60 (45--71)\^58 (46--68)\^Parish 201464.4 ± 10.262.7 ± 13.7Pontes-Arruda 200664.3 ± 18.766 ± 20Pontes-Arruda 201170 (64--78)\^72 (65--82)\^Rice 201155.5 ± 17.052.9 ± 16.5Shirai 201571 (66--77)\^74 (60--80)\^Singer 200657.0 ± 18.762.3 ± 17.2Stapelton 201149.0 ± 16.550.7 ± 16.5Thiella 201249.3 ± 20.753.1 ± 19.3Tihista 201738.7 ± 16.241.6 ± 16.6Weimann 199834.8 ± 16.931.0 ± 11.8Van Zanten 201457 ± 1959 ± 18[^2]Table 3Tolerability of enteral fish oil supplementation.Table 3StudyNausea/ vomitingDyspepsiaHigh GRVAspirationDiarrheaConstipationAbdominal distentionIleusPancreatitisCalories deliveredReplace tubeAchieved feeding targetTriglyceridesProkineticsOverall GI complicationsAtkinson 1998*Intervention*NRNRNSDNRNSDNRNRNRNR14 (0--32)[a](#tbl3fnStar){ref-type="table-fn"} kcal/kg/dayNR50/197NRNRNR*Control*NRNRNSDNRNSDNRNRNRNR13 (0--32)[a](#tbl3fnStar){ref-type="table-fn"} kcal/kg/dayNR51/193NRNRNRBower 1995*Intervention*NSDNRNR1/147NSDNRNRNSDNRNRNSD100/147NRNRNR*Control*NSDNRNR1/132NSDNRNRNSDNRNRNSD100/132NRNRNRElamin 2012*Intervention*NRNRNRNRNRNRNRNRNRNRNR9/9NRNRNR*Control*NRNRNRNRNRNRNRNRNRNRNR8/8NRNRNRGadek 1999*Intervention*1/700/70NR1/705/70NR2/701/702/70NR1/7050/7028% decrease on day 7NRNR*Control*1/761/76NR0/765/76NR4/761/761/76NR5/7643/7619% decrease on day 7NRNRGalban 2000*Intervention*NRNRNRNR20/89NRNRNRNR1231 ± 411 kcal/dayNRNRNRNR48/89*Control*NRNRNRNR12/87NRNRNRNR1414 ± 471 kcal/dayNRNRNRNR56/87Grau-Carmona 2011*Intervention*NRNR220 episodes/1000 days of ENNR271 episodes/1000 days of ENNRNRNRNR1718 (1189--1956) kcal/dayNRNSD120.3 ± 40.3 mg/dLNRNR*Control*NRNR279 episodes/1000 days of ENNR302 episodes/1000 days of ENNRNRNRNR1599 (1351--1976) kcal/dayNRNSD106.9 ± 41.9 mg/dLNRNRHosny 2013*Intervention*NRNRNRNR5/25NRNRNRNRNRNRNRNRNRNR*Control*NRNRNRNR4/25NRNRNRNRNRNRNRNRNRNRJakob 2017*Intervention*NRNRNRNR29/45NRNRNRNR18.0 (12.5--20.9) kcal/kg/dayNRNRNR15/45NR*Control*NRNRNRNR31/44NRNRNRNR19.7 (17.3--23.1) kcal/kg/dayNRNRNR15/44NRKagan 2015*Intervention*NRNRNRNR1.1 ± 2.3 episodesNRNRNRNR1612.8 ± 532.6 kcal/dayNR52/62NRNRNR*Control*NRNRNRNR1.6 ± 4.4 episodesNRNRNRNR1622.9 ± 728 kcal/dayNR52/58NRNRNRKieft 2005*Intervention*NRNRNRNRNRNRNRNRNRNRNRNRNRNRNR*Control*NRNRNRNRNRNRNRNRNRNRNRNRNRNRNRKudsk 1996*Intervention*NRNRNRNRNSDNRNSDNRNR18.03 ± 1.62 kcal/kg/dayNRNRNSD on day 7NR13/16*Control*NRNRNRNRNSDNRNSDNRNR18.29 ± 1.60 kcal/kg/dayNRNRNSD on day 7NR16/17Mendez 1997*Intervention*NRNRNRNR150-400 mL/dayNRNRNRNR29.5 ± 2.6 kcal/kg/dayNRNRNRNRNR*Control*NRNRNRNR300-700 ml/dayNRNRNRNR26.5 ± 3.2 kcal/kg/dayNRNRNRNRNRMesejo 2015*Intervention*NRNR1/52NR2/52NR0/52NRNR22.2 ± 4.1 kcal/kg/dayNRNRNSDNRNR*Control*NRNR3/105NR4/105NR1/105NRNR21.7 ± 4.8 kcal/kg/dayNRNRNSDNRNRParish 2014*Intervention*NRNRNSDNRNSDNRNRNRNRNSDNRNRNRNRNR*Control*NRNRNSDNRNSDNRNRNRNRNSDNRNRNRNRNRPontes-Arruda 2006*Intervention*0/551/55NRNR9/55NRNRNR0/551621 ± 48 kcal/day2/5514/55NRNRNR*Control*1/480/48NRNR7/48NRNRNR1/481647 ± 74 kcal/day4/4823/48NRNRNRPontes-Arruda 2011*Intervention*2/53NRNRNR4/53NRNRNRNR1538 (1295--1890) kcal/dayNRNRNRNRNR*Control*3/53NRNRNR7/53NRNRNRNR1523 (1370--1950) kcal/dayNRNRNRNRNRRice 2011*Intervention*3.8%NR3.2%NR28.7%NR9.3%NRNRNRNRNRNRNRNR*Control*2.4%NR4.0%NR20.9%NR7.4%NRNRNRNRNRNRNRNRShirai 2015*Intervention*0/23NRNRNR6/23NR0/23NRNR18.78 (18.12--20.21) kcal/kg/dayNRNR110 (94--131) mg/dL on day 14NRNR*Control*0/23NRNRNR4/23NR0/23NRNR19.48 (15.73--20.68) kcal/kg/dayNRNR92 (79--123) mg/dL on day 14NRNRSinger 2006*Intervention*NRNRNRNRNRNRNRNRNR1624 ± 512 kcal/dayNR46/46NRNRNR*Control*NRNRNRNRNRNRNRNRNR1420 ± 437 kcal/dayNR49/49NRNRNRStapelton 2011*Intervention*NRNRNRNRNRNRNRNRNR7362 ± 3800 kcal/weekNRNRNRNRNR*Control*NRNRNRNRNRNRNRNRNR7495 ± 3831 kcal/weekNRNRNRNRNRThiella 2012*Intervention*NRNRNRNRNRNRNRNRNRNRNRNRNRNRNR*Control*NRNRNRNRNRNRNRNRNRNRNRNRNRNRNRTihista 2017*Intervention*NRNR4/47NR2/4745/47NRNRNR16 ± 4 kcal/kg/dayNRNRNRNRNR*Control*NRNR15/45NR7/4540/45NRNRNR17 ± 3 kcal/kg/dayNRNRNRNRNRWeimann 1998*Intervention*NRNR466 ± 262 mLNR4/163/16NRNRNR561 ± 266 kcal/day1 (1--4)NRNRNRNR*Control*NRNR513 ± 154 mLNR4/136/13NRNRNR520 ± 342 kcal/day1 (1--3)NRNRNRNRVan Zanten 2014*Intervention*NRNRNRNR1/152NRNRNRNRNRNRNRNRNRNR*Control*NRNRNRNR0/149NRNRNRNRNRNRNRNRNRNR[^3][^4]

2. Experimental design, materials and methods {#s0010}
=============================================

The search strategy, study identification and selection criteria used to acquire the data presented in this article are reported in [@bib1].

Transparency document. Supplementary material {#s0025}
=============================================

Supplementary material.

None.

Transparency data associated with this article can be found in the online version at <https://doi.org/10.1016/j.dib.2018.10.017>.

[^1]: EPA: eicosapentaenoic acid; DHA: docosahexaenoic acid; NR: not reported; NS: non-significant; IQR: interquartile range; LCP: long-chain polyunsaturated fatty acids.

[^2]: Age is reported in mean ± standard deviation unless otherwise specified. \* median with range \^ median with interquartile range ^\#^ mean ± standard error of the mean.

[^3]: GRV: gastric residual volume; GI: gastro-intestinal; NR: not reported; NSD: non-significant difference; IQR: interquartile range; EN: enteral nutrition.

[^4]: IQR with range; NR = not reported; NSD = no significant difference, no absolute numbers reported in article.
